Sanofi Publishes 2021 Report on Principles in Prescription Drug Pricing, Notes $890 Million in Patient Assistance Programs

March 8, 2021

Unjustified price increases continue to be a point of contention in the pharma industry. Sanofi has published a report aimed at improving transparency related to drug price increases. Notably, Sanofi announces price decreases of 7.8% in 2020. The report details $543 million in savings for patients via copay assistance programs and $890 million in medication dispensed via patient assistance programs. Sanofi has also decreased the net price of insulin by 53% since 2012, although out of patient costs have risen significantly.

According to the report, “We acknowledge our role in preserving the sustainability of our health care system and in limiting our contribution to U.S. health care spending growth. Should we take a list price increase on one of our medicines, our guiding principle is to limit the total annual increase during our fiscal year (Jan. 1 to Dec. 31) to a level at or below the projected growth rate for National Health Expenditures for said year.” Read the report here.

(Source: Sanofi, 2021)

Share This Story!